European Academy of Allergy and Clinical Immunology

Policing Pollution: EAACI Supports World Environment Day

Retrieved on: 
Wednesday, June 5, 2019
Medical specialties, Medicine, European Academy of Allergy and Clinical Immunology, Immunology, Igor P. Kaidashev

EAACI supports World Environment Day, a United Nations-led event which this year tackles the theme of air pollution.

Key Points: 
  • EAACI supports World Environment Day, a United Nations-led event which this year tackles the theme of air pollution.
  • We want to treat our patients, but we also want to prevent the causes of the disease," says Maria Neira, Director Department of Public Health and Environment, World Health Organisation in a plea to EAACI Annual Congress 2019 participants.
  • The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956.
  • EAACI is dedicated to improving the health of people affected by allergic diseases.

KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology

Retrieved on: 
Tuesday, June 4, 2019
Health, Biotechnology, Pharmaceutical, Complement deficiency, RTT, Medical specialties, Medicine, Health, Angioedema, Hereditary angioedema, European Academy of Allergy and Clinical Immunology, Kallikrein, Medication

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors announced data was presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors announced data was presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal.
  • We continue recruiting for our Phase 2 clinical trial of KVD900, said Andrew Crockett, Chief Executive Officer of KalVista.
  • KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.
  • KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

mAPPing the New World of Allergy at EAACI Annual Congress 2019

Retrieved on: 
Tuesday, June 4, 2019
Medical specialties, Immunology, Medicine, Allergology, European Academy of Allergy and Clinical Immunology, Allergen immunotherapy, Allergy, Rhinitis, Allergen, Allergic rhinitis, Draft:Denisa Dizdarevic, Igor P. Kaidashev

LISBON, June 4, 2019 /PRNewswire/ --The European Academy for Allergy and Clinical Immunology (EAACI) Annual Congress presents new avenues for controlling allergic rhinitis and asthma by mHealth technology.

Key Points: 
  • LISBON, June 4, 2019 /PRNewswire/ --The European Academy for Allergy and Clinical Immunology (EAACI) Annual Congress presents new avenues for controlling allergic rhinitis and asthma by mHealth technology.
  • The role of mHealth in monitoring and predicting curative treatment of allergic disease by allergen immunotherapy is also highlighted.
  • The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956.
  • With more than11,000 members from 122 countries and over 75 National Allergy Societies, EAACI is the primary source of expertise in Europe for all aspects of allergy.

mAPPing the New World of Allergy at EAACI Annual Congress 2019

Retrieved on: 
Tuesday, June 4, 2019
Medical specialties, Immunology, Medicine, Allergology, European Academy of Allergy and Clinical Immunology, Allergen immunotherapy, Allergy, Rhinitis, Allergen, Allergic rhinitis, Draft:Denisa Dizdarevic, Igor P. Kaidashev

LISBON, June 4, 2019 /PRNewswire/ --The European Academy for Allergy and Clinical Immunology (EAACI) Annual Congress presents new avenues for controlling allergic rhinitis and asthma by mHealth technology.

Key Points: 
  • LISBON, June 4, 2019 /PRNewswire/ --The European Academy for Allergy and Clinical Immunology (EAACI) Annual Congress presents new avenues for controlling allergic rhinitis and asthma by mHealth technology.
  • The role of mHealth in monitoring and predicting curative treatment of allergic disease by allergen immunotherapy is also highlighted.
  • The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956.
  • With more than11,000 members from 122 countries and over 75 National Allergy Societies, EAACI is the primary source of expertise in Europe for all aspects of allergy.

Stallergenes Greer Will Be at 2019 EAACI Congress and Present the Results of Its Phase III House Dust Mites Tablet Trial

Retrieved on: 
Friday, May 31, 2019
Health, Biotechnology, Clinical trials, Hospitals, Pharmaceutical, General Health, Medical specialties, Immunology, Medicine, Allergology, Stallergenes Greer, Allergen immunotherapy, Allergen, Allergic rhinitis, Rhinitis, Allergy, European Academy of Allergy and Clinical Immunology, House dust mite

Scientific presentations will detail the results of its Phase III clinical trial evaluating the efficacy and safety of its sublingual allergy immunotherapy tablet STAGR320 for the treatment of house dust mite-induced allergic rhinitis.

Key Points: 
  • Scientific presentations will detail the results of its Phase III clinical trial evaluating the efficacy and safety of its sublingual allergy immunotherapy tablet STAGR320 for the treatment of house dust mite-induced allergic rhinitis.
  • Detailed results of our STAGR320 trial will be shared at EAACI 2019.
  • These results illustrate Stallergenes Greers determination to develop a large portfolio of treatment options, including sublingual tablet treatments.
  • This was the largest phase III clinical trial conducted to evaluate the treatment of house dust mite allergy in adult and adolescent patients.

Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress

Retrieved on: 
Friday, May 24, 2019
Health, Biotechnology, Pharmaceutical, Medical specialties, Immunology, Medicine, Food allergies, RTT, European Academy of Allergy and Clinical Immunology, Peanut allergy, Allergy, Peanut, Tree nut allergy, HAL Allergy Group, Book:Allergies

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient quality of life data at the European Academy of Allergy and Clinical Immunology (EAACI) 2019 Congress, taking place June 1 to 5, 2019, in Lisbon, Portugal.

Key Points: 
  • Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient quality of life data at the European Academy of Allergy and Clinical Immunology (EAACI) 2019 Congress, taking place June 1 to 5, 2019, in Lisbon, Portugal.
  • In addition, we are also pleased to be presenting data that underscore the real-world effects of living with peanut allergy as reported by patients themselves.
  • The data will be presented as follows:
    Title: Allergy to Peanut ImPacting Emotions and Life (APPEAL) 2: The First European Multi-Country Qualitative Evaluation of the Impact of Living with Peanut Allergy.
  • This press release concerns AR101, a product candidate that is under clinical investigation, and AR201, a product candidate that Aimmune expects will be under clinical investigation in 2019.

European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint

Retrieved on: 
Monday, March 25, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Children, Consumer, Medical specialties, Immunology, Medicine, Food allergies, RTT, Allergen immunotherapy, Allergology, Immunotherapy, Peanut allergy, European Academy of Allergy and Clinical Immunology, Allergy, Tree nut allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success), met its primary efficacy endpoint.

Key Points: 
  • Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success), met its primary efficacy endpoint.
  • Aimmune plans to present full results in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in early June.
  • Based on these positive results, Aimmune intends to submit a marketing authorization application (MAA) for AR101 to the European Medicines Agency (EMA) in mid-2019.
  • In connection with this announcement, Aimmune Therapeutics will host a conference call and webcast today at 8:30 a.m. EDT.